New drug IBI115 enters human testing for tough lung cancer
NCT ID NCT07559019
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called IBI115, alone or with other treatments, in 150 people with advanced small cell lung cancer. The main goals are to check safety, find the right dose, and look for early signs that the drug might help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI115
- What this could lead to
- If it works, this could point toward a new treatment option for advanced small cell lung cancer.
- What could go wrong
- This is a very early Phase 1 trial with only 150 people. The main goal is safety, not proof of effectiveness. Many drugs fail at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER ( SCLC ) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the second affiliated hospital of AMU
RECRUITINGChongqing, Chongqing Municipality, 400037, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at stubborn lung cancer
- Could a hidden nerve condition be more common in lung cancer than we think?
- Can a gentler drug trio tame small cell lung cancer in older patients?
- Experimental combo aims to tackle Treatment-Resistant cancers
- New PET scan targets hidden lung cancer cells
- New drug THE-0504 enters human testing for tough cancers